ʻO Cabozantinib Nā moʻolelo kūleʻa e pili ana i ka mālama ʻana iā Caner - AASraw
Hana ʻo AASraw i ka paukū Cannabidiol (CBD) a me ka Hemp Essential Oil i ka nui!

ʻO Cabozantinib

 

    1. Hōʻike Cabozantinib
    2. ʻO Cabozantinib Mekanism o ka Hana
    3. Nā hopena ʻaoʻao Cabozantinib
    4. ʻO ka hoʻomohala hou loa o Cabozantinib
    5. Nā Cabozantinib Hana Hoʻolālā Nā Moʻolelo
    6. hōʻuluʻulu manaʻo

 

ʻO Cabozantinib Description

ʻO Cabozantinib (CAS:849217-68-1) hoʻohana ʻia e mālama i ka maʻi ʻaʻai nui loa, i kekahi manawa me ka hoʻohui ʻia me kahi lāʻau ʻē aʻe i kapa ʻia ʻo nivolumab. Hoʻohana ʻia ʻo Cabozantinib e mālama i ka maʻi ʻaʻai ate i ka poʻe i mālama mua ʻia me ka sorafenib. Hoʻohana ʻia ʻo Cabozantinib e mālama i ka maʻi ʻaʻai thyroid i pāhola ʻia i nā wahi ʻē aʻe o ke kino. Hiki ke hoʻohana ʻia ʻo Cabozantinib no nā kumu i helu ʻole ʻia i kēia alakaʻi lāʻau.

 

ʻO Cabozantinib Hoʻolaha i ka hana

ʻO ka hopena pahuhopu ka hopena o kahi o 100 mau makahiki o ka noiʻi i hoʻolaʻa ʻia i ka hoʻomaopopo ʻana i nā ʻokoʻa ma waena o nā hunaola maʻi ʻaʻai a me nā hunaola maʻamau. I kēia lā, ua kau nui ka mālama ʻana i ka maʻi ʻaukā ma ka luku ʻana i ka hoʻokaʻawale wikiwiki ʻana i nā hunaola no ka mea ʻo kahi hiʻohiʻona o nā hunaola maʻi ʻo ia ka hoʻokaʻawale wikiwiki ʻana. Minamina, ua hoʻokaʻawale wikiwiki ʻia kekahi o kā mākou mau pūnaewele maʻamau, e hoʻoulu ana i nā hopena ʻaoʻao he nui.

Hoʻomakaʻia ka hopena e pili ana i kaʻikeʻana i nā hiʻohiʻona'ē aʻe o nā pūnaepe pūpū. ʻImi nā kānakaʻepekema i nāʻano likeʻole o nā pūnaeho pūpū me nā pūnaewele maʻamau. Hoʻohanaʻia kēiaʻikepili no ka hanaʻana i kahi lāʻau hoʻohālikelike e hōʻeuʻeu i nā pūnaewele kanalē me kaʻole e loaʻa nā pūnaewele maʻamau, a laila e alakaʻi ana i nā hopena piliʻole. ʻO nāʻano o keʻano o keʻano o keʻano heʻe keʻano, heʻano liʻiliʻi wale nō ia, akā, hoʻopili nā mea a pau i ka hikiʻana o ke kiko pukupuku e ulu, puʻunaue, hoʻoponopono a / aiʻole e launa pū me nā pūnaewele'ē aʻe.

Loaʻa nāʻano likeʻole o nā hoʻoponopono i hoʻopiliʻia, i ho'ākākaʻia ma nāʻano ākeaʻekolu. ʻO kekahi mau mea i hoʻoponoponoʻia e nānā i nā māhele o loko a me ka hana o ka pūkuniaʻau maʻi. Hoʻomaʻoʻia nā papa hana i nā'ōmike liʻiliʻi e hiki ke komo i loko o ka hale kamela a hoʻopau i ka hana o nā pūnaewele, e make ai lākou. Aia kekahi mauʻano o ka hoʻohālikelike i hilinaʻiʻia e nānā i nāʻaoʻao i loko o nā pūnaewele. Nā pahuhopu pahuhopu hou i hoʻolālāʻia i ke kuhi o ka pūnaewele. Hoʻomaopopoʻia nā hōʻailona e hilinaʻi i nā hopenaʻo ia nāʻano'elepoki monoclonal. Hoʻopā nā mea hoʻopuka āpau Antiangiogenesis i nā ipu koko e hāʻawi ana i ka oxygen i loko o nā pūnaewele, i ka hopena e hoʻonā ai i nā pūnaewele i ka pōloli.

ʻO Cabozantinib kahi lāʻau i hoʻomākaukau ʻia e kia a hoʻopaʻa ʻia i ka nā mea loaʻa o ka tyrosine kinase a me nā mea hōʻemi ka hana o nā kinase tyrosine he nui, me RET, MET, a me VEGF ma ka ʻili o ka pūnaewele. Ma ka hoʻopaʻa ʻana i kēia mau mea loaʻa, pale nā ​​cabozantinib i nā ala nui e hāpai i ka mahele o ka pūnaewele.

Ke hoʻomau nei ka hoʻomauʻana eʻike i kahi o nā maʻi lapaʻau e hiki ke kōkua maikaʻiʻia me nā hoʻolālā i kālaiʻia a eʻike i nā hiʻona hou aʻe no ka nui o nā maʻi maʻi.

 

ʻO Cabozantinib Nā Huaʻaoʻao

E kiʻi i ke kōkua lapaʻau kūikawā inā loaʻa iāʻoe nā hōʻailona o ka hopena maʻi: hives; ka hanu pilikia; ka pehu o kou mau maka, kou lehelehe, kou lehelehe, a me kou puʻu.

Hiki iā Cabozantinib ke hana i kahi perforation (kahi puka a waimaka paha) a i ʻole kahi fistula (kahi ala hele hewa) ma loko o kou ʻōpū a me kou ʻōpū. Kāhea i kāu kauka inā loaʻa iā ʻoe ka ʻeha o ka ʻōpū koʻikoʻi, a i ʻole inā manaʻo ʻoe e ʻokiʻoki a me ka gagging ke ʻai ʻoe a inu paha.

Kāhea koke i kāu kauka inā loaʻa iāʻoe:

▪ ʻeha poʻo poʻo, ʻike maka ʻole, kuʻi i kou ʻāʻī a pepeiao paha;

▪ ʻO ka luaʻi, diarrhea, a i ʻole ka constipation e ʻino a mau ana;

▪ Ka pehu ʻana i kou mau lima, nā lima, nā wāwae, a me nā wāwae;

▪ ʻĀpiki maʻalahi a hoʻokahe paha (ka ihu, kahe koko, kahe nui o ka menstrual, a i ʻole nā ​​kahe koko e kū ʻole);

▪ Ka noho koko a i ʻole hoʻoluhi, ʻūlū me ka mucus koko a i ʻole ka luaʻi e like me ke kope;

▪ Jaundice (melemele o ka ʻili a i ʻole nā ​​maka);

▪ Ka ʻeha, ʻūlū, kahe ʻana ke kahe, a i ʻole nā ​​ʻāwīwī nui ma nā poho o kou mau lima a i ʻole nā ​​kapuaʻi o kou mau wāwae;

▪ Ka huikau, nā pilikia noʻonoʻo, nāwaliwali, nā loli o ka hihiʻo, ka hopu ʻana;

▪ He poʻo poʻo māmā, e like paha me ʻoe e make ai;

▪ Ka ʻeha a i ʻole ka helu ʻana o ka iwi a, ʻāʻulaʻula a pehu paha, niho leʻaleʻa, a me ka hoʻōla lohi ma hope o ka hana niho;

▪ Helu liʻiliʻi ke keʻokeʻo haʻahaʻa – ke kuni, ka ʻeha o ka waha, ka ʻeha o ka ʻili, ʻeha ka puʻu, ka ʻū, pilikia ka hanu ʻana;

▪ Nā pilikia o ka ʻaihue adrenal – kahe, ka luaʻi, ka luhi nui loa, ka luhi, nāwaliwali, maʻule; a i ʻole

▪ Nā hōʻailona o ka hahau a i ʻole ke kōkō ʻana o ke koko – ka helu a me ka nāwaliwali paha ma kekahi ʻaoʻao o kou kino, nā pilikia me ka ʻike a kaulike paha, ka pilikia e ʻōlelo a hoʻomaopopo paha i ka mea e ʻōlelo ʻia iā ʻoe, ka ʻeha o ka umauma, ka hanu ʻana i ka hanu, ka pehu ʻana a i ʻole ka ʻeha ma ka lima a me ka wāwae. .

E hoʻopaneʻe a hoʻopau ʻia paha kāu mau kaha o cabozantinib i ka wā e hiki mai ana inā he mau hopena ʻē aʻe kāu.

ʻO AASraw ka mea hana hana ʻo Cabozantinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Hiki ke komo i nā hopenaʻaoʻao maʻamau:

▪ ʻeha o ka ʻōpū, nausea, luaʻi, nalo o ka makemake ʻole, pākī, paʻa paʻa;

▪ ʻeha, ʻulaʻula, pehu, a ʻeha hoʻi i kou waha a i ʻole puʻu;

▪ Pilikia i ka ʻōlelo ʻana, hoʻololi i ka ʻono;

▪ Nā hōʻailona anuanu e like me ka ihu ihu, ka ʻū ʻana, ka ʻāʻī ʻeha, kahe.

▪ ʻehu;

▪ ʻeha ma kou mau mākala, nā iwi, a me nā ami;

▪ Nā hoʻāʻo ʻana o ke akepaʻa maʻamau a i ʻole nā ​​hoʻokolohua koko ʻē aʻe;

▪ Manaʻo luhi;

▪ Ka hoʻēmi kino; a i ʻole

▪ E māmā ana ka waihoʻoluʻu o ka lauoho.

ʻAʻole kēia he papa inoa piha o nā hopena pili a hiki i nā mea'ē aʻe. Kāhea i kāu kauka no ka'ōlelo aʻo kino no nā hopenaʻaoʻao. Hiki iāʻoe ke hōʻike i nā hopena'ē aʻe i ka FDA ma 1-800-FDA-1088.

 

Hoʻolālā Hou o ʻO Cabozantinib 

Ua hāʻawi ʻia ʻo Cabozantinib i ke kūlana lāʻau makua ʻole e ka US Food and Drug Administration (FDA) i Nowemapa 2010 a i Pepeluali 2017.

Ua waiho aku ʻo Exelixis i kahi noi lāʻau hou me ka FDA i ka hapa mua o 2012 a ma Nowemapa 29, 2012 cabozantinib i kāna capsule form i ʻae ʻia e ka US FDA ma lalo o ka inoa Cometriq no ka mālama ʻana i nā mea maʻi me ka maʻi maʻi thyroid medullary. ʻae ʻia i ka European Union no ke kumu like i 2014.

I Malaki 2016 ua laikini ʻo Exelixis iā Ipsen nā kuleana o ka honua (ma waho o ka US, Kanada, a me Iapana) e kūʻai aku iā cabozantinib.

Nā hopena hoʻokolohua a Exelixis 'Phase III o ka hoʻāʻo ʻana i ka lāʻau i ka puʻuwai Ka maʻi 'aʻai paʻi ʻia ma ka NEJM ma 2015. I ʻApelila 2016 ua ʻae ka FDA no ke kūʻai aku ʻana i ka papa papa ma ke ʻano he laina laina lua no ka hakuʻala Ka maʻi 'aʻai a ua ʻae ʻia ka mea like i ka European Union i Sepatemaba o kēlā makahiki.

I Kēkēmapa 2017, ua ʻae ka FDA i cabozantinib (Cabometyx, Exelixis, Inc.) no ka mālama ʻana i ka poʻe me ka maʻi puʻuwai puʻuwai puʻuwai (RCC). Ua hoʻokumu ʻia ka ʻae ma ka ʻikepili mai CABOSUN (NCT01835158), kahi papa inoa multicenter phase II i hoʻopaʻa inoa ʻia i 157 poʻe i komo me ka RCC waena a maikaʻi ʻole hoʻi i mālama ʻole ʻia.

I Ianuali 2019, ka Ua ʻae ʻo FDA i ka cabozantinib (Cabometyx, Exelixis, Inc.) no ka poʻe me ka maʻi hepatocellular carcinoma (HCC) i mālama mua ʻia me ka sorafenib. Hoʻokumu ʻia ka ʻae ma luna o CELESTIAL (NCT01908426), kahi makapō (2: 1), makapō makapō, hoʻokolohua hoʻokolohua, hoʻokolokolo multicenter i nā poʻe komo me HCC i loaʻa mua i ka sorafenib a he keiki Pugh Class A kīnā ʻole ka ate.

Ke ʻimi ʻia nei ʻo Cabozantinib no ka pono ma ke ʻano he lapaʻau no ka neurofibromatosis type 1.

Ua ʻae ʻia e ka Food and Drug Administration (FDA) ka cabozantinib no ka mālama ʻana i ka maʻi hepocellular i nā mea maʻi i loaʻa i ka sorafenib ma mua.

Cabozantinib kahi oral tyrosine kinases mea kāohi o MET, VEGFR, a me AXL. Hoʻokomo nā kinases tyrosine kineta i nā hana nui i nā hana pūnaewele maʻamau a me nā kaʻina pathologic, e like me ka oncogenesis, metastasis, tum angiogenesis, a me ka mālama ʻana o microen environment.

Ua ʻae mua ka FDA i ka cabozantinib no ka mālama ʻana i ka medullary maʻi ʻaʻai thyroid. Ma hope, ua ʻae ka FDA i kāna hoʻohana ʻana i ka carcinoma cell cell.

 

Nā Cabozantinib Hana Hoʻolālā Nā Moʻolelo 

Moʻolelo 1: Hoʻomaʻamaʻa ʻo Cabozantinib i ka lālani mua o ka Carenaloma Renal Cell Advanced

Ma Kēkēmapa 19, 2017, ua ʻae ʻia ka US Food and Drug Administration (FDA) i ka cabozantinib (Cabometyx) no ka mālama ʻana i nā mea maʻi me ka carcinoma cell renal advanced (RCC).

Ua ʻae ka FDA i ka cabozantinib ma 2016 no ka mālama ʻana i nā mea maʻi me ka RCC holomua i loaʻa i ka lāʻau antiangiogenic ma mua. Hāʻawi ka ʻae o kēia lā no ka mālama ʻana i ka hoʻonohonoho laina mua.ʻO Cabozantinib

Ua hoʻokumu ʻia kēia ʻae ma ka ʻikepili mai ka hoʻokolokolo ʻana o CABOSUN, kahi papa inoa multicenter phase II i wehe ʻia i 157 mau maʻi me ka RCC waena a me ka pilikia maikaʻi ʻole i mālama ʻole ʻia ma mua. Loaʻa nā maʻi i ka cabozantinib (n = 79) 60 mg waha waha i kēlā me kēia lā a i ʻole sunitinib (Sutent) (n = 78) 50 mg waha waha i kēlā me kēia lā (4 mau pule ma ka hoʻomaʻamaʻa a ukali ʻia e 2 mau pule) a hiki i ka holomua ʻana o ka maʻi a i ʻole ka ʻawahia ʻae ʻole ʻia. Kuhi ʻia ke ola waena manuahi-ʻole (e like me ka loiloi ʻia e ke kōmike loiloi radiology kūʻokoʻa) no nā mea maʻi e lawe ana i ka cabozantinib he 8.6 mau mahina (95% wā hilinaʻi [CI] = 6.8-14.0) i hoʻohālikelike ʻia me nā mahina 5.3 (95% CI = 3.0-8.2) no nā mea maʻi e lawe ana i ka sunitinib (hazard ratio = 0.48; 95% CI = 0.31-0.74; P = .0008).

ʻO ka hopena i hōʻike pinepine ʻia (≥ 25%) nā hopena maikaʻi ʻole ma ka cabozantinib clinical program he diarrhea, luhi, nausea, hoʻemi i ka makemake, hypertension, palmar-plantar erythrodysesthesia, ka pohō kaumaha, ka luaʻi, dysgeusia, a me ka stomatitis.

ʻO ka hopena pinepine loa o 3-4 mau hopena maikaʻi (≥ 5%) i nā maʻi i mālama ʻia me cabozantinib ma CABOSUN he hypertension, diarrhea, hyponatremia, hypophosphatemia, palmar-plantar erythrodysesthesia, luhi, ALT hoʻonui, hoʻemi i ka makemake, stomatitis, ʻeha, hypotension, a syncope. ʻO ka mahele lāʻau i koi ʻia o cabozantinib he 60 mg waha, hoʻokahi i kēlā me kēia lā.

ʻAe ʻia ʻo Cabozantinib no ka lapaʻau ʻana o maʻi ʻaʻai thyroid a ua kūʻai ʻia aku ma lalo o ka inoa ʻo Cometriq. ʻO Cometriq a me Cabometyx he mau formulate ʻokoʻa a ʻaʻole hiki ke loli.

 

mo'olelo 2: Mālama ʻo Cabozantinib iā Medullary thyroid Cancer

Ua ʻae ka FDA i ka cabozantinib (Cometriq) e mālama ai i ka maʻi ʻaʻai thyroid medastatic (MTC) i Nowemapa 2012. Ua hoʻokumu ʻia ia ma nā hopena mai kahi international, multicenter, randomized, double-blind, kāohi hoʻokolokolo me nā kumuhana 330. Pono nā mea i komo e hōʻike i ka maʻi holomua i loko o 14 mau mahina ma mua o ke komo ʻana i hoʻopaʻa ʻia, i hōʻoia ʻia ma o ke kōmike loiloi radiology kūʻokoʻa a i ʻole ke kauka lapaʻau.

Hoʻohui ʻia nā mea maʻi e loaʻa i kahi cabozantinib 140 mg a i ʻole placebo waha i hoʻokahi manawa i kēlā me kēia lā a hiki i ka maʻi holomua a i ʻole ka ʻino kūpale ʻole. Hoʻonohonoho ʻia ka Randomization e like me ka makahiki <65 makahiki vs> 65 mau makahiki a me ka hoʻohana mua ʻana o kahi mea kāohi inhibitor tyrosine.ʻO Cabozantinib

ʻO nā wahi kiko mua ke ola manuahi o ka holomua (PFS), ka pane pahuhopu (OR), a me ka lōʻihi o ka pane e hoʻohana ana i nā pae hoʻohālikelike RESIST. ʻO nā mea maʻi i ka hui cabozantinib ua hoʻolōʻihi iā PFS ke hoʻohālikelike ʻia me ka poʻe e loaʻa ana i kahi placebo (P <.0001). ʻO ka mea kikoʻī, ʻo PFS median i ka lima cabozantinib he 11.2 mau mahina a me ka PFS waena ma ka placebo lima he 4.0 mau mahina.

ʻO nā mea maʻi wale nō e lawe ana iā cabozantinib i ʻike i kahi pane hapa (27% vs 0; P <.0001). Eia kekahi, ʻo ka lōʻihi ma waena o OR he 14.7 mau mahina no ka poʻe i mālama ʻia me ka lāʻau. ʻAʻohe mea nui i ke ola holoʻokoʻa i ʻike ʻia ma waena o nā lima.

I ka 2019 meta- a me ka hoʻokele waiwai e loiloi ana i ka pono o cabozantinib a me vandetanib i nā mea maʻi o ʻEnelani National Health Service, Tappenden et al. Hoʻopau ʻia.

"Hōʻike nā hōʻike i hōʻike ʻia e hoʻomaikaʻi ka cabozantinib a me ka vandetanib i ka PFS ma mua o ka placebo; akā naʻe, ʻaʻole hōʻike ʻia nā pono OS nui. Kuhi ʻia nā loiloi hoʻokele waiwai i loko o ka heluna lehulehu o ka EU-label, ʻo ka ICERs [incremental cost-effective ratios] no cabozantinib a me vandetanib he> £ 138,000 no kēlā QALY (makahiki ola i hoʻoponopono ʻia i ka maikaʻi) i loaʻa. Ma loko o ka heluna o ka EU (European Union) -label heluna kanaka, ka ICER no vandetanib e manaʻo ʻia e lilo> £ 66,000 no kēlā QALY i loaʻa. "

 

mo'olelo 3: Mālama Cabozantinib ʻO Hepatocellular Carcinoma

I Ianuali 2019, ua ʻae ʻo FDA i nā papa cabozantinib no nā mea maʻi me maʻi kanesa hepatocellular (HCC) i mālama mua ʻia me sorafenib. Ua hoʻokumu ʻia ka ʻae ma nā hopena mai ka hoʻokolokolo CELESTIAL.

I ka randomized (2: 1), pālua makapō, placebo-kāohi, multicenter hoʻokolokolo, nā mea maʻi i randomized i cabozantinib 60 mg waha waha i kēlā me kēia lā (n = 470) a i ʻole placebo (n = 237) a hiki i ka manawa o ka holomua o ka maʻi a ʻae ʻole paha. ʻawahia.ʻO Cabozantinib

ʻO ka piko mua ka OS. ʻO PFS a me ORR, i loiloi ʻia e nā mea ʻimi noiʻi e hoʻohana ana iā RECIST 1.1, ua ana ʻia hoʻi. Ua pili ka hoʻohana ʻo Cabozantinib me kahi OS waena o 10.2 mau mahina (95% CI: 9.1-12.0) me 8 mau mahina (95% CI: 6.8-9.4) no ka poʻe e loaʻa ana kahi placebo (HR 0.76; 95% CI: 0.63, 0.92; P = .0049). ʻO Median PFS he 5.2 mau mahina (4.0-5.5) i ka lima cabozantinib i hoʻohālikelike ʻia me 1.9 mau mahina (1.9-1.9) i ka lima placebo (HR 0.44; 95% CI, 0.36, 0.52; P <.001). ʻO ka ORR he 4% (95% CI, 2.3, 6.0) i ka poʻe e lawe ana i ka cabozantinib me 0.4% (95% CI, 0.0, 2.3) i ka poʻe e lawe ana i ka placebo.

ʻOi aku ka kiʻekiʻe o nā hanana ʻehā a 3 paha i nā mea maʻi e lawe ana i ka cabozantinib (4%) ma mua o ka poʻe e lawe ana i kahi placebo (68%).

Ua hoʻopau nā mea kākau o ka hoʻokolokolo CELESTIAL me ka mea penei: "Ma waena o nā mea maʻi me ka maʻi i hana mua ʻia me ka maʻi hepatocellular carcinoma, ʻo ka mālama ʻana me cabozantinib ka hopena o ke ola holoʻokoʻa a me ke ola me ka holomua ʻole ma mua o placebo. ʻO ke kaʻina o nā hanana ʻino maikaʻi loa ma ka hui cabozantinib ma kahi o ʻelua mau manawa i ʻike ʻia i ka hui placebo. "

 

hōʻuluʻulu manaʻo

ʻO Cabozantinib kahi mea kāpae tyrosine kinase i hoʻohana ʻia e mālama i ka carcinoma kōkō ʻoi loa, ka maʻi hepatocellular, a me ka maʻi ʻaʻai thyroid medullary. Ua ʻae mua ʻia ʻo Cabozantinib i ka makahiki 2012 a ʻo ia ka mea kūpili non-kikoʻī tyrosine kinase. Ua ʻae mua ʻia ma ka US ma lalo o ka inoa ʻo Cometriq, i kuhikuhi ʻia no ka mālama ʻana i ka maʻi maʻi thyroid medastatic.ʻO Cabometyx) ua ʻae ʻia no ka hoʻomaʻamaʻa ʻana i ka carcinoma cellenalenal holomua, a ua loaʻa i kēia formulation like ke ʻae ʻia i ka US a me Kanada i ka makahiki 2019 no ka mālama ʻana i ka carcinoma hepatocellular i nā mea maʻi i mālama mua ʻia.

ʻO AASraw ka mea hana hana ʻo Cabozantinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Reference

[1] Choueiri TK, Escudier B, Powle T, a me al. ʻO Cabozantinib me everolimus i ka carcinoma cell renal holomua (METEOR): nā hopena hope loa mai kahi hoʻokolohua kaulike, hāmama inoa, pae 3 hoʻokolokolo. Lancet Oncol. 2016; 17: 917–27.

[2] ʻO Tappenden P, Carroll C, Hamilton J, et al. ʻO Cabozantinib a me vandetanib no ke kūleʻa ʻole kūloko kūloko a metastatic medullary thyroid cancer: kahi ʻōnaehana loiloi a me ke ʻano hoʻokele waiwai. Loiloi Technol Health. 2019; 23: 1-144.

[3] George DJ, Hessel C, Halabi S, et al. ʻO Cabozantinib vs. sunitinib no nā mea maʻi i hana ʻole ʻia me ka maʻi puʻuwai puʻuwai holomua o ka wā waena a i ʻole ka pōpilikia maikaʻi ʻole: ka hōʻuluʻulu subgroup o ka hoʻokolokolo ʻo Alliance A031203 CABOSUN. ʻĀnekolohua. 2019; 24: 1-5.

[4] Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ , Salgia R: Haʻawina o XL184 (Cabozantinib), kahi mea hoʻōki i ka tyrosine kinase waha, i nā mea maʻi me ka maʻi ʻaʻai thyroid medullary. ʻO J Clin Oncol. 2011 Jul 1; 29 (19): 2660-6. hana: 10.1200 / JCO.2010.32.4145. Epub 2011 Mei 23.

[5] Abou-Alfa GK, Meyer T, Cheng AL, et al. ʻO Cabozantinib i nā mea maʻi me ka carcinoma hepatocellular holomua a holomua. N Engl J Med. 2018; 379: 54-63.

[6] ʻO US Food and Drug Administration. Ua ʻae ʻo FDA i ka cabozantinib no ka maʻi maʻi hepatocellular. Loaʻa ma: https://www.fda.gov/drugs/fda-approves-cabozantinib-hepatocellular-carcinoma Loaʻa iā ʻAukake 28, 2019.

[7] Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC , Joly AH: Cabozantinib (XL184), kahi puke MET a me VEGFR2 mea kāohi, i ka manawa like kaomi i ka metastasis, angiogenesis, a me ka ulu ulu ʻana. Mol Kukuna Ther. 2011 Dec; 10 (12): 2298-308. hana: 10.1158 / 1535-7163.MCT-11-0264. Epub 2011 Sep 16.

[8] "Hoʻonui ʻia ka lāʻau cabozantinib i ka lāʻau lapaʻau thyroid i ka PFS". Archive from the original on 2012-04-02. Ua kiʻi ʻia 24 ʻOkakopa 2011.

[9] "ʻO Cabozantinib Orphan Hoʻolālā Hoʻolālā a me nā ʻApono". ʻO ka US Food and Drug Administration (FDA). 29 Nowemapa 2010. Ua kiʻi ʻia 11 Nowemapa 2020.

0 Likes
6605 Views

E hiki no hoi i like

Comments ua paa.